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A B S T R A C T   
Plasma high density lipoprotein (HDL) exhibits many functions that render it an effective endothelial protective 
agent and may underlie its potential role in protecting the maternal vascular endothelium during pregnancy. In 
non-pregnant individuals, the HDL lipidome is altered in metabolic disease compared to healthy individuals and 
is linked to reduced cholesterol efflux, an effect that can be reversed by lifestyle management. Specific sphin-
golipids such as sphingosine-1-phosphate (S1P) have been shown to mediate the vaso-dilatory effects of plasma 
HDL via interaction with the endothelial nitric oxide synthase pathway. This review describes the relationship 
between plasma HDL and vascular function during healthy pregnancy and details how this is lost in pre- 
eclampsia, a disorder of pregnancy associated with widespread endothelial dysfunction. Evidence of a role for 
HDL sphingolipids, in particular S1P and ceramide, in cardiovascular disease and in healthy pregnancy and pre- 
eclampsia is discussed. Available data suggest that HDL-S1P and HDL-ceramide can mediate vascular protection 
in healthy pregnancy but not in preeclampsia. HDL sphingolipids thus are of potential importance in the healthy 
maternal adaptation to pregnancy.   
1. Background 
High density lipoprotein (HDL) cholesterol has a well-established 
inverse association with atherosclerosis. Theoretically, increasing HDL 
plasma concentrations should lead to less atherosclerosis-related dis-
ease. Unfortunately, clinical trials of HDL cholesterol-raising medication 
repeatedly failed to reduce the risk of atherosclerotic incidence despite 
elevations in HDL cholesterol concentration [1–3]. As increasing HDL 
cholesterol concentrations does not diminish the risk of atherosclerotic 
vascular disease, attention has instead shifted toward HDL composition 
and functionality. 
In pregnancy, there is a physiological metabolic adaptation involving 
insulin resistance, inflammation and oxidative stress which could cause 
vascular damage. Surprisingly, pregnant women have enhanced 
vascular function despite this unfavorable environment. The reasons for 
this phenomenon still require elucidation. One possible protective factor 
may be HDL via its vascular protective properties. HDL concentration is 
increased in healthy pregnant women and its composition might be 
involved in functionality [4,5]. So far, little is known about alterations of 
HDL composition and function in healthy pregnancy and preeclampsia. 
Here we focus on the sphingolipid composition of HDL and the role of 
sphingolipids in healthy pregnancy and preeclampsia. 
2. Protective role of HDL against atherosclerotic vascular 
disease 
HDL particles contain approximately 50% protein and 50% lipid 
with phospholipid, cholesteryl ester, free cholesterol and sphingolipid as 
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the major lipid components. The major protein in HDL is apolipoprotein 
A-I (apoA-I) which is involved in HDL synthesis and represents 70% of 
the total protein in mature HDL particles. 
HDL has a wide range of functions, all of which could help protect 
against vascular dysfunction. Firstly, reverse cholesterol transport is a 
process whereby HDL promotes cholesterol efflux from various cell 
types. Cholesterol efflux capacity of HDL shows an inverse relationship 
with both carotid intima-media thickness and the likelihood of angio-
graphic coronary artery disease, independently of the HDL cholesterol 
level [6]. Removing excess cholesterol from lipid-laden macrophages is 
a crucial process in HDL-mediated vascular protection. 
Secondly, HDL has antioxidant properties whereby it can remove and 
inactivate lipid peroxides from LDL and cells. A number of HDL- 
associated components are involved in lipid peroxide inactivation 
including apoA-I, paraoxonase-1, platelet-activating factor acetylhy-
drolase and lecithin-cholesterol acyltransferase (reviewed in [7]). 
Thirdly, HDL can enhance vascular function by modulating endo-
thelial nitric oxide synthase (eNOS) expression, leading to increased 
nitric oxide (NO) production and vasodilation [8]. There are several 
components of HDL known to take part in HDL-induced NO production. 
ApoA-I in HDL is required for interaction with scavenger receptor class B 
type 1 (SR-B1) and stimulates eNOS activity [9]. In addition HDL 
sphingolipids, such as sphingosine-1-phosphate (S1P), can act via the 
lysophospholipid receptor S1P3 to induce vasodilatory effects [10]. 
Lastly, HDL is thought to protect against chronic inflammation in 
atherosclerosis. HDL has been shown to inhibit the expression of 
monocyte chemoattractant protein, an important pro-inflammatory 
chemokine in endothelial cells [11]. It can also reduce tumor necrosis 
factor α (TNFα) -stimulated expression of pro-atherogenic adhesion 
molecules, such as vascular cell adhesion molecule-1 (VCAM-1), 
through both scavenger receptor class B type 1 (SR-B1) and S1P re-
ceptors [12,13]. 
A study in patients with metabolic syndrome demonstrated altered 
HDL lipidome and lower cholesterol efflux capacity compared to a 
healthy population. Interestingly, management by weight loss and ex-
ercise could modify the patients’ HDL lipidome toward that of healthy 
individuals and improve its cholesterol efflux function [14]. These re-
sults emphasize the link between HDL composition and function and 
changes in HDL composition may play a key role in pathological 
processes. 
3. The role of HDL in pregnancy 
3.1. Healthy pregnancy 
During pregnancy, maternal metabolic adaptation occurs to provide 
energy and nutrition for fetal development. In early pregnancy, there is 
normal or slightly enhanced insulin sensitivity, increased maternal fat 
deposition and lipogenesis. By mid-gestation, there is a switch to a 
catabolic state where insulin resistance and lipolysis increase to improve 
availability of glucose and lipids to the fetus. Inflammation, coagulation 
and oxidative stress are also elevated in the latter half of pregnancy. 
Despite this unfavorable environment in healthy pregnancy, vascular 
function appears to be enhanced. Healthy pregnant women have lower 
systemic vascular resistance due to vasodilation, leading to a gradual 
decrease in blood pressure until 20 weeks of gestation. After that, blood 
pressure rises to the pre-pregnant level (reviewed in [4]). 
From 10 weeks of pregnancy, HDL continues to rise and reaches its 
peak concentration (42% increase) at 20 weeks of gestation, followed by 
a slow fall to a plateau (7% above early pregnant level) after which HDL 
remains stable until delivery (reviewed in [4]). As mentioned earlier, 
HDL plays a key role in preventing vascular dysfunction. Thus, HDL may 
also exert protective effects in healthy pregnancy. Both the quantity and 
quality of HDL could be involved in this protection. 
3.2. Preeclampsia 
Preeclampsia is characterized by the new onset of gestational hy-
pertension with proteinuria or end-organ dysfunction. Primarily, clin-
ical manifestations of preeclampsia result from a generalised maternal 
endothelial dysfunction. The pathogenesis of maternal vascular 
dysfunction in preeclampsia is still unclear. One possible mechanism is 
abnormal development of placental vasculature resulting in placental 
hypoperfusion/ischemia and release of antiangiogenic factors to disturb 
maternal endothelial function. Other pathways could be via maternal 
co-morbidities that predispose to vascular insufficiency. However, these 
mechanisms do not occur in all patients with preeclampsia. Pre-
eclampsia is known as a multi-factorial disorder and has been catego-
rized into two phenotypes: early-onset preeclampsia and late-onset 
preeclampsia. Early-onset preeclampsia, developing before 34 weeks of 
gestation, tends to be associated with placental impairment, intrauterine 
growth restriction, multi-organ dysfunction and detrimental maternal 
and neonatal outcomes. Whereas late-onset preeclampsia, developing at 
or after 34 weeks of gestation, is likely to result from maternal under-
lying disease and leans toward a normal placenta and normal fetal 
growth (reviewed in [15]). 
Similar to healthy pregnant women, HDL plasma concentration in 
patients with preeclampsia increases during the gestational period when 
compared to non-pregnant women. However, the increase in HDL levels 
in preeclampsia is less and HDL is at significantly lower concentrations 
than in normal pregnancy [16]. Therefore, reduced amounts of HDL 
which may be dysfunctional occur and could fail to protect maternal 
endothelial function in preeclampsia. 
4. Sphingolipids 
Sphingolipids including sphingosine-1-phosphate (S1P) and cer-
amide are involved in many biological signaling pathways. S1P in HDL 
particles (HDL-S1P) has significant anti-atherosclerotic properties. The 
ceramide content in HDL (HDL-ceramide) could also have a role in 
vascular function. In this section, the evidence for the role of HDL-S1P 
and HDL-ceramide in cardiovascular disease and in pregnancy is 
discussed. 
4.1. Sphingolipid metabolism 
Ceramide can be synthesized through three pathways. First is de 
novo synthesis. Sphinganine can be esterified by a family of ceramide 
synthases (CERS) 1–6 to form dihydroceramide and then ceramides of 
different acyl-chain lengths dependent on the specificities of each CERS. 
Ceramide can be converted to other complex sphingolipids such as 
sphingomyelin. Other pathways for generating ceramide are sphingo-
myelin hydrolysis, by the enzyme sphingomyelinase, and the salvage 
pathway that allows complex sphingolipids to be converted back into 
ceramide. 
All sphingolipids are eventually catabolized to ceramide which can 
be converted to sphingosine and sphingosine-1-phosphate (S1P) by the 
enzymes ceramidase and sphingosine kinase (SPHK) respectively. S1P 
production is controlled by reversible phosphorylation via S1P phos-
phatase (SGPP) and irreversible degradation by S1P lyase (SGPL). 
4.2. Sphingolipids in HDL 
The source of HDL-S1P could be hepatocytes where HDL synthesis 
mainly occurs and there is research showing that disturbance of lipid 
handling in the liver can lead to decreased S1P in HDL [17]. Other major 
sources of S1P that may be acquired during circulation of HDL in the 
plasma are blood cells and endothelial cells [18–20]. Several trans-
porters are proposed to transfer S1P to HDL, for example, ATP-binding 
cassette transporter (ABCC1) and spinster homolog 2 (SPNS2). An 
ABCC1 inhibitor, MK-571, exhibited an inhibitory effect on S1P 
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transport to HDL in vitro, but there was no difference in S1P transport 
between Abcc1-deficient mice and wildtype controls [21]. Potentially, 
SPNS2 has shown a role in intracellular S1P export and S1P levels in 
plasma and HDL profoundly decreased in Spns2− /− mice [22,23]. 
Therefore, SPNS2 can be considered as the most likely transporter for 
S1P. In HDL, apolipoprotein M (apoM) is a specific carrier of S1P that 
can moderate HDL-S1P homeostasis. It can promote S1P efflux from 
erythrocytes, physically protect S1P from its degrading enzymes and 
thus increase HDL-S1P levels [21,24]. 
With respect to ceramide, subspecies of ceramide with fatty acid 
chain lengths of 24:0, 24:1, 23:0, 22:0 and 16:0 are the major subspecies 
in HDL [25]. There is no evidence of direct efflux of ceramide from cells 
to lipoproteins. However, ceramide can be incorporated into newly 
synthesized very low density lipoprotein (VLDL) and low density lipo-
protein (LDL) in the Golgi and secreted within these lipoproteins into 
plasma [26–28]. Ceramide then could be transferred to nascent HDL 
from VLDL or LDL remnants in plasma. The proteins thought to transfer 
ceramides are cholesteryl ester transfer protein (CETP) and PLTP which 
are involved in the transfer of other sphingolipids between lipoproteins 
[29] (Fig. 1). 
4.3. Role of HDL-sphingolipids in metabolic and cardiovascular disease 
4.3.1. S1P 
HDL-S1P is well-known for its role in protection against atheroscle-
rosis. HDL-S1P plays a key role in vascular barrier function by main-
taining tight junctions between endothelial cells and preventing 
inflammation-induced vascular leakage [30–32]. HDL-S1P also pro-
motes survival, proliferation and migration of endothelial cells and 
vascular smooth muscle cells. Lastly, HDL-S1P regulates vascular tone 
by inducing nitric oxide synthase (eNOS) and production of 
cyclooxygenase-2 and prostaglandin I2 (reviewed in [33,34]). HDL-S1P 
is involved in both vasodilation and vasoconstriction, but the most sig-
nificant messenger increased by HDL is nitric oxide which leads to 
Fig. 1. HDL sphingolipids metabolism and effect on vascular function. 
The source of HDL-S1P could be hepatocytes where HDL synthesis mainly occurs or may be acquired during circulation of HDL in the plasma from blood cells and 
endothelial cells. Ceramide can be incorporated into newly synthesized VLDL and LDL from liver and secreted within these lipoproteins into plasma, ceramide then 
could be transferred to HDL. HDL-S1P and HDL-ceramide exert their role in vascular protection through various pathways. In HDL particles, ApoM enhances S1P’s 
affinity for the S1PR1 and S1PR3 receptor which predominantly protect endothelial function. S1P-S1PR1 and S1P-S1PR3 signaling help maintain endothelial cell-cell 
junction, promote cell survival and proliferation, and enhance vasodilation through eNOS and COX-2 stimulation. On the other hand, apoM in HDL weakens S1P’s 
affinity for the S1PR2 receptor, resulting in reduced macrophage recruitment and PAI-1 expression, thus diminished inflammation and thrombosis. Binding of HDL to 
SR-BI leads to increased intracellular total ceramide level which is involved in the vasodilatory effects of HDL by stimulating eNOS. Ceramide also increases ABCA1 
expression which improves cholesterol efflux to HDL. The sources of ceramide in this process could be from HDL particles, especially HDL-C24 ceramide which 
inversely relate with cardiovascular disease. 
HDL-S1P; S1P in HDL, HDL-ceramide; ceramide in HDL, S1P; sphingosine-1-phosphate, VLDL; very low density lipoprotein, LDL; low density lipoprotein, S1PR1–3; 
S1P receptors 1–3, eNOS; endothelial nitric oxide synthase, NO; nitric oxide, COX-2; cyclooxygenase-2, PGI2; prostaglandin I2, PAI-1; plasminogen activator 
inhibitor-1, SR-BI; scavenger receptor class B type I, ABCA1; ATP Binding Cassette transporter Subfamily A Member 1, apoM; apolipoprotein M, apoA-I; apolipo-
protein A-I. 
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vasodilation. Impaired HDL-induced eNOS activity has been found in 
metabolic syndrome patients [35]. This impairment was explained by 
reduced S1P content in HDL and was normalized by S1P enrichment of 
HDL [35]. 
In the pathogenesis of atherosclerosis, circulating S1P acts as an 
extracellular ligand for S1P receptors (S1PR1–5) which exert a variety of 
effects. S1PR1 and S1PR3 receptors predominantly exert anti- 
atherosclerotic actions, whereas S1PR2 exerts pro-atherosclerotic ef-
fects. S1PR2 signaling augments plasminogen activator inhibitor-1 (PAI- 
1) expression which lead to thrombosis and also induces macrophage 
recruitment and inflammation [36,37]. Meanwhile, HDL-S1P has a 
distinct role in protecting against atherosclerosis as described earlier. 
ApoM can be a vital player in this protective role. ApoM seems to 
enhance S1P’s affinity for the S1PR1 receptor while weakening its af-
finity for the S1PR2 receptor (reviewed in [38]). Thus, ApoM drives 
HDL-S1P action toward the anti-atherosclerosis pathway (Fig. 1) 
4.3.2. Ceramide 
Ceramide has different effects on metabolic and cardiovascular dis-
ease depending whether it is carried by HDL or not. In tissues, ceramide 
appears to be involved in inflammation, insulin resistance and impaired 
vascular function, which can lead to metabolic and cardiovascular dis-
orders (reviewed in [39,40]). Similarly, elevated plasma ceramide levels 
were found in poor cardiorespiratory fitness and type 2 diabetes and also 
show a strong relationship with cardiovascular death [41]. However, 
HDL-ceramide seems to have the opposite properties toward metabolic 
and cardiovascular disease. Studies in LDL- and VLDL-depleted, HDL- 
containing fractions of serum exhibited an inverse relationship between 
C24:1 ceramide level and the incidence of ischemic heart disease [42]. 
Additionally, sphingolipidome analysis of HDL in type 1 diabetes pa-
tients showed a lower proportion of total ceramide on the surface of HDL 
[43]. A decreased HDL-ceramide level is associated with metabolic and 
cardiovascular disease. However, further investigation is needed to 
confirm the role of ceramide in HDL. 
Regarding its contribution to the protective roles of HDL, ceramide 
appears to enhance the anti-atherogenic function of HDL. Several studies 
indicated that ceramide treatment increases ATP-binding cassette 
transporter expression which increases binding of ApoA-I to cells and 
improves cholesterol efflux to ApoA-I [44,45]. Furthermore, ceramide is 
involved in the vasodilatory effects of HDL by stimulating eNOS to the 
same extent as HDL [46]. Binding of HDL to SR-BI can also lead to 
increased intracellular total ceramide levels, eNOS stimulation and 
vasodilation [46]. The source of ceramide in this process is still unclear. 
Ceramide may come from caveolae released by sphingomyelinase ac-
tivity or be provided directly from HDL particles [46]. If the latter sit-
uation is true, HDL ceramide could have a protective effect against 
cardiovascular disease. 
Ceramide functional effects may be heterogeneous due to distinct 
fatty acid chain lengths defining different functions of ceramide. Much 
research suggests a reciprocal relationship between long-chain (C16 and 
C18) and very-long-chain (C24) ceramides. Higher ceramide C16:0 and 
lower ceramide C24:0 were found in HDL of type 1 diabetes patients 
Fig. 2. Sphingolipids and HDL roles in healthy pregnancy and preeclampsia. 
S1P and ceramide appear to be crucial in normal pregnancy. After decidualization of endometrium, SPHK I and SGPP I expression were up-regulated, while SGPL I 
expression was not, suggesting high turnover of S1P and a role for S1P in normal decidualization in pregnancy. Increased plasma HDL and apoM concentration, 
together with more S1PR1 expression than S1PR2 expression shown in omental arteries, myometrial arteries and chorionic plate arteries, lead to improved maternal 
vascular function. EVT migration and trophoblast invasion are also enhanced via S1P interaction with S1PR1 in healthy pregnancy, but inhibited by S1P-S1PR2 
signaling. Under low oxygen conditions, impaired sensitivity to hypoxia of placenta and an inability to up-regulate SPHKI expression were found in preeclamp-
sia. Also, in preeclampsia, decreased S1PR1 and S1PR3 receptors and increased S1PR2 receptor in placenta suggest impaired EVT migration and trophoblast invasion. 
The increased de novo synthesis subsequent to SPT activation and decreased breakdown of ceramides via diminished acid ceramidase expression resulting in cer-
amide accumulation, cell death and impaired trophoblast invasion in preeclampsia. Compared to healthy pregnancy, lower HDL concentration, increased plasma 
C16:0, C18:0, C20:0, C22:0 and C24:1 ceramide at 32 weeks of gestation, and decreased C24:0 ceramide concentration at 32–36 weeks of gestation in preeclampsia 
could lead to endothelium and liver impairment. 
S1P; sphingosine-1-phosphate, S1PR1–3; S1P receptors 1–3, SPHK I; sphingosine kinase I, SGPP I; S1P phosphatase I, SGPL I; S1P lyase I, apoM; apolipoprotein M, 
EVT; extravillous trophoblast, SPT; serine-palmitoyltransferase. 
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[43]. Similarly, plasma ceramide C16:0 and C24:0 ratio strongly relate 
to cardiovascular events [41]. A study in a mouse model of atheroscle-
rosis and non-alcoholic fatty liver disease also found increased hepatic 
levels of ceramide C16:0 and C18:0 and decreased C24:0. Inhibition of 
ceramide synthesis normalized hepatic ceramide levels (reduced long- 
chain ceramides and increased very-long-chain ceramide), and 
decreased atherosclerosis and hepatic steatosis [47]. Consistently, ex-
periments in CERS2 heterozygous transgenic mice, which have reduced 
very-long-chain ceramide synthesis, reveal compensatory increases in 
long-chain ceramide leading to susceptibility to insulin resistance and 
dysregulated lipid metabolism [48]. Therefore, a balance between long- 
chain and very-long-chain ceramides may play a crucial role in meta-
bolic and cardiovascular disease (Fig. 1). 
4.4. Role of sphingolipids in healthy pregnancy 
Sphingolipid metabolism has unique characteristics in pregnancy. 
Serine-palmitoyltransferase (SPT), the rate-limiting enzyme in the de 
novo synthesis pathway, has three subunits, SPTLC1, 2 and 3. Distinct 
from other subunits, STPLC3 expression is strikingly high in placenta 
and it enables generation of the uncommon C16 sphingoid backbone and 
a special methylated C18-based sphingolipid which are both present in 
the HDL fraction [49–51]. This raises the possibility that these unique 
sphingolipids in HDL could contribute to its improved function in 
pregnancy. However, the physiological role of these sphingolipids in 
HDL and also in pregnancy is still unclear. Undeniably, while there are 
some data on plasma sphingolipids, there is limited research regarding 
the role of HDL-sphingolipids in the metabolism and vascular function of 
pregnancy. Nevertheless, studies of S1P and ceramide in other aspects of 
reproduction, as described below, provide potentially relevant infor-
mation (Fig. 2). 
4.4.1. S1P 
S1P appears to be crucial in the development of endometrial and 
placental tissue during pregnancy. In the early stages of pregnancy, 
proliferative human endometrial stromal cells show high expression of 
enzymes involved in S1P metabolism including sphingosine kinase I 
(SPHK I), S1P phosphatase I (SGPP I) and S1P lyase I (SGPL I) [52]. After 
decidualization, SPHK I and SGPP I expression were up-regulated, while 
SGPL I expression was not, suggesting high turnover of S1P [52]. Protein 
expression and activity of SPHK I in decidua increased as gestational age 
increased [53]. High SPHK activity and high turnover of S1P suggest 
that S1P might be important in normal decidualization in pregnancy. 
After implantation, trophoblast development and invasion take place 
to drive placental formation. S1P was shown to inhibit cytotrophoblast 
differentiation during trophoblast development [54,55]. However, S1P 
effects on trophoblast invasion are heterogenous depending on which 
S1P receptor S1P interacts with. S1P promotes extravillous trophoblast 
(EVT) migration via interaction with S1PR1 receptors on EVT, while it 
inhibits EVT migration via S1PR2 receptors [56,57]. S1P also affects 
human decidual natural killer (dNK) cell function involved in tropho-
blast invasion and spiral artery remodeling [58]. Modulation of the S1P 
pathway can down-regulate S1PR5 receptor expression on dNK cells and 
impair dNK-mediated EVT migration and endothelial angiogenesis [58]. 
Thus, the activity of the S1P synthetic pathway could be involved in EVT 
migration and spiral artery remodeling during pregnancy. 
At term, the type of S1P receptors expressed on arteries suggests a 
role for HDL-S1P in pregnancy. S1P effects on atherosclerosis depend on 
the type of S1P receptor and HDL-S1P appears to enhance agonist 
properties on S1PR1 (the anti-atherosclerotic receptor) [38]. There are 
several types of arteries from healthy pregnant women that show more 
S1PR1 expression than S1PR2 (pro-atherosclerotic receptor) expression 
including omental arteries, which represent the maternal systemic 
vasculature; myometrial arteries, which give a focus on uterine vascular 
function; and chorionic plate arteries, which affect the fetal-placental 
circulation [59,60]. These findings support the idea that HDL-S1P may 
protect vascular function in both the maternal and placental circulation 
in pregnancy. 
Plasma apoM concentration significantly increases throughout 
pregnancy and reaches peak concentration in the postpartum period 
[61]. This pattern parallels that of HDL concentration which increases 
during pregnancy and remains stable in third trimester until around 10 
weeks after delivery [4]. These data suggest that the apoM as well as the 
S1P content of HDL is increased in pregnancy and may lead to enhanced 
HDL function in pregnancy. Although there was no difference in plasma 
apoM concentration among healthy pregnancy and other complicated 
pregnancies such as preeclampsia, gestational diabetes, recurrent 
miscarriage and small-for-gestational age babies, the link between apoM 
production and maturity onset diabetes of the young type 3 (MODY3) 
could provide some hint of a role for apoM in healthy pregnancy [61]. 
ApoM synthesis is regulated by the transcription factor HIF-1α as 
reduced apoM expression was specifically found in HNF1A − /− mice 
and MODY3 patients (who have mutation in HNF1A), but not type 1 
diabetes mellitus [62–64]. Interestingly, MODY3 is associated with an 
increased risk of gestational diabetes mellitus (GDM) and unlike other 
MODYs, MODY3 does not result in elevation of fetal birthweight 
[65,66]. These findings suggest a correlation between decreased apoM 
expression and increased risk of GDM and, thus, a role for apoM in 
maintaining healthy pregnant metabolic adaptation. 
4.4.2. Ceramide 
The most abundant ceramide species in healthy pregnant women are 
C24:0 and C24:1 [67,68]. Plasma C24:0, C18:0 and C16:0 concentra-
tions continuously increased from the 1st trimester to 3rd trimester, 
whereas C24:1 ceramide does not change throughout pregnancy [68]. 
Additional data regarding ceramide metabolism in pregnancy come 
from studies in livestock. Healthy bovine pregnancy has metabolic ad-
aptations similar to pregnant humans (increased insulin resistance and 
lipolysis). In overweight pregnant cattle, most plasma ceramides are 
further increased, relative to those with a lean phenotype, during pre- 
and post-partum [69,70]. Hepatic total ceramide and C24:0 ceramide 
progressively rose during the late gestational period in overweight cows 
[70]. There was also a linear relationship between increased plasma 
fatty acid and increased hepatic lipid accumulation in overweight 
pregnant cows, indicating improved fatty acid supply for ceramide 
synthesis in the liver [69,70]. The results of this research support the 
idea that ceramide may be involved in accelerated insulin resistance in 
overweight pregnancy due to elevated circulating fatty acids in over-
weight individuals that enhance ceramide synthesis and accumulation 
in liver and plasma, leading to hepatic lipid accumulation and insulin 
resistance. 
4.5. Role of sphingolipids in preeclampsia 
4.5.1. S1P 
The S1P pathway appears to be involved in the placental dysfunction 
of preeclampsia. In normotensive patients, exposure of human placental 
chorionic villous explants to low oxygen content increased SPHK I 
mRNA and protein levels [71]. However, reduction of placental SPHK1 
gene expression and protein were found in patients with preeclampsia 
[71]. These finding suggest impaired sensitivity to hypoxia of placenta 
in pre-eclampsia and an inability to up-regulate SPHK I expression. Also, 
down-regulated mRNA expression of angiogenic S1P receptors (S1PR1 
and S1PR3) in placenta and up-regulated mRNA expression of anti- 
angiogenic S1P receptors (S1PR2) in chorionic villi were observed in 
preeclampsia [71]. Thus, an altered S1P/S1P receptor interaction may 
have an important role in the aberrant angiogenesis observed during 
placentation in preeclampsia. 
Studies on levels of plasma S1P in preeclampsia relative to those in 
healthy pregnancy are inconsistent. A study in patients with mild pre-
eclampsia shows increased plasma S1P concentrations, while another 
study focused on early-onset preeclampsia revealed decreased serum 
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S1P concentrations [72,73]. This could be due to differences in S1P 
levels between serum and plasma or due to the severity of preeclampsia 
[67]. Nevertheless, in the same group of patients with preeclampsia 
whose serum S1P was lower than in healthy controls, higher C16, C18, 
C20 and C24 ceramide concentrations were found in both serum and 
placental tissue [73]. These data point to a possible role of S1P-ceramide 
imbalance in preeclampsia (Fig. 2). 
4.5.2. Ceramide 
There is evidence that disruption of ceramide metabolism is involved 
in placental impairment and cell death in early-onset preeclampsia. In 
placenta, higher ceramide accumulation occurs in early-onset pre-
eclampsia compared to healthy pregnancy. Imaging and immunofluo-
rescent staining of placenta also demonstrated higher C16:0 and C24:0 
in trophoblast layers and syncytial knots from placenta in preeclampsia. 
The increased ceramides were the result of increased de novo synthesis 
subsequent to SPT activation and decreased breakdown of ceramides to 
sphingosine in lysosomes via diminished ASAH1 (acid ceramidase gene) 
expression and activity [73]. In the same way, oxidative stress can 
reduce ASAH1 expression resulting in C16:0 and C18:0 ceramide accu-
mulation [73]. Additionally, C16:0 ceramide was shown to trigger 
apoptosis, autophagy and necroptosis in trophoblast cells [73,74]. 
Necroptosis can interfere with the normal process of trophoblast cell 
fusion which may contribute to aberrant trophoblast invasion [74]. 
Thus, elevated de novo synthesis together with oxidative stress-induced 
reduction of lysosomal breakdown favors ceramide accumulation, 
leading to placental dysfunction and cell death in preeclampsia. 
Compared to healthy pregnancy, increased plasma C16:0, C18:0, 
C18:1, C20:0, C22:0 and C24:1 ceramide were found in preeclampsia at 
around 32 weeks of gestation [72,73]. Because syncytial knots normally 
shed into the maternal circulation, increased ceramide accumulation in 
syncytial knots could be the origin of elevated plasma ceramide con-
centration in early-onset preeclampsia. Plasma C24:0 ceramide con-
centration declined at 32–36 weeks of gestation in preeclampsia 
compared to healthy pregnancy [68]. As mentioned earlier, decreased 
circulating C24:0 ceramide is associated with liver cirrhosis and car-
diovascular disease, thus reduced C24:0 ceramide found in 3rd trimester 
of preeclampsia may correlate with liver impairment and cardiovascular 
complications in preeclampsia [41,75] Fig. 2. 
5. Conclusion 
To provide an appropriate nutrient environment for the fetus, 
healthy pregnant women adapt their metabolism leading to insulin 
resistance, lipolysis and inflammation. Although this adaptation could 
be harmful for vessels, pregnant women surprisingly have enhanced 
vascular function. Evidence supports a possible role for HDL in exerting 
protective properties in healthy pregnancy and these may fail to occur in 
preeclampsia, leading to vascular dysfunction. S1P and ceramide show 
significant effects in healthy pregnancy and preeclampsia. However, 
focusing on HDL composition and functionality, there are few data 
available on the role of HDL-S1P and HDL-ceramide during pregnancy. 
Such data as there are suggest potential roles for HDL-S1P and HDL- 
ceramide mediating vascular protection in healthy pregnancy and 
failing in preeclampsia, however further research is needed to add to the 
limited evidence base. 
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